AHL
BPMC

Abel Hall LLC’s Blueprint Medicines BPMC Stock Holding History

Abel Hall LLC’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,846
Closed -$237K – 330
2025
Q2 		$237K Buy
+1,846
New +$192K 0.11% 202

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Abel Hall LLC's BPMC Position: Q3 2025 in Review

Abel Hall LLC sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,846 shares — an estimated $237K sold.

Abel Hall LLC first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $237K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Abel Hall LLC reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Abel Hall LLC sold 1,846 Blueprint Medicines shares in Q3 2025, an estimated $237K.
  • Abel Hall LLC first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Abel Hall LLC's Blueprint Medicines position peaked at $237K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Abel Hall LLC's 13F filing for Q3 2025, filed 17 Nov 2025.